ELEVATED MULTI-BIOMARKER DISEASE ACTIVITY (MBDA) PREDICTS RELAPSES IN RA PATIENTS IN SUSTAINED REMISSION TAPERING TUMOUR NECROSIS FACTOR INHIBITOR THERAPY-RESULTS FROM THE RANDOMIZED CONTROLLED RETRO STUDY

Rech J, Hagen M, Englbrecht M, Haschka J, Reiser M, Kleyer A, Hueber A, Manger B, Figuereido C, Cobra JF, Tony HP, Finzel S, Kleinert S, Wendler J, Schuch F, Ronneberger M, Feuchtenberger M, Fleck M, Manger K, Ochs W, Schmitt-Haendle M, Lorenz HM, Nüsslein H, Alten R, Henes J, Krueger K, Schett G (2017)

Publication Type: Conference contribution

Publication year: 2017

Journal

Annals of the Rheumatic Diseases BMJ Publishing Group

Book Volume: 76

Pages Range: 516-517

Authors with CRIS profile

Hans Jürgen Rech Department of Medicine 3 – Rheumatology and Immunology Bernhard Manger Professur für Rheumatologie und Klinische Immunologie Karin Manger Medizinische Fakultät Hubert Nüsslein Medizinische Fakultät Georg Schett Lehrstuhl für Innere Medizin III

Involved external institutions

Schlosspark-Klinik DE Germany (DE) Ruprecht-Karls-Universität Heidelberg DE Germany (DE) Praxiszentrum St. Bonifatius DE Germany (DE) Eberhard Karls Universität Tübingen DE Germany (DE) Medias Klinikum DE Germany (DE) Julius-Maximilians-Universität Würzburg DE Germany (DE) Medizinische Universität Wien AT Austria (AT) Universitätsklinikum Freiburg DE Germany (DE) Asklepios Kliniken DE Germany (DE)

How to cite

APA:

Rech, J., Hagen, M., Englbrecht, M., Haschka, J., Reiser, M., Kleyer, A.,... Schett, G. (2017). ELEVATED MULTI-BIOMARKER DISEASE ACTIVITY (MBDA) PREDICTS RELAPSES IN RA PATIENTS IN SUSTAINED REMISSION TAPERING TUMOUR NECROSIS FACTOR INHIBITOR THERAPY-RESULTS FROM THE RANDOMIZED CONTROLLED RETRO STUDY. (pp. 516-517).

MLA:

Rech, Jürgen, et al. "ELEVATED MULTI-BIOMARKER DISEASE ACTIVITY (MBDA) PREDICTS RELAPSES IN RA PATIENTS IN SUSTAINED REMISSION TAPERING TUMOUR NECROSIS FACTOR INHIBITOR THERAPY-RESULTS FROM THE RANDOMIZED CONTROLLED RETRO STUDY." 2017. 516-517.

BibTeX: Download